Opportunity to Improve Outcomes in At-Risk Patients
Enveric Biosciences seeks to advance novel combinations of CBD with chemotherapeutic agents and immunotherapies. Preclinical data suggests combination therapies may improve the activity of certain chemotherapies or cancer immunotherapies, potentially enabling more potent or longer-lasting therapeutic effects. In addition, combination therapies may allow for the same or greater therapeutic effect with a lower dose of the chemotherapeutic agent, potentially minimizing the severity of side effects.
Because cancer cells contain largely the same proteins and other targets as the healthy cells in the body, there are few cancer-specific druggable targets; chemotherapies often simply target all rapidly-proliferating cells in the body. While chemotherapy can be successful in suppressing tumors, there are many side effects associated with use; side effects may increase with higher doses.
The ability to provide the same or greater therapeutic effect with a smaller overall dose of the chemotherapeutic agent may minimize the risk and severity of side effects in subjects and allow for the treatment of certain patients with weakened immune systems.
Enveric Biosciences Intellectual Property
Enveric Biosciences holds full or limited rights to several patents as an in-licensee covering the use of CBD, including the use of CBD with current cancer treatments, both broadly and for specific cancer types.
Enveric Biosciences’ in-licensed patent applications claim specific varieties of cannabis plants, and claim the use of CBD in treatment of other diseases including multiple sclerosis and inflammatory bowel disease.
Advancing Novel Therapies Across Multiple Indications
Enveric Biosciences has a robust pipeline with multiple data points expected in 2021 for radiodermatitis, glioblastoma and chemotherapy-induced neuropathy.